SRR1340133
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.346
- ALLOGRAFT_REJECTION+0.334
- IL2_STAT5_SIGNALING+0.334
- INTERFERON_GAMMA_RESPONSE+0.329
- INTERFERON_ALPHA_RESPONSE+0.323
- ANGIOGENESIS+0.320
- TNFA_SIGNALING_VIA_NFKB+0.308
- CHOLESTEROL_HOMEOSTASIS+0.271
- APOPTOSIS+0.257
- IL6_JAK_STAT3_SIGNALING+0.254
Top 10 suppressed
- MYC_TARGETS_V2-0.430
- E2F_TARGETS-0.318
- G2M_CHECKPOINT-0.307
- DNA_REPAIR-0.292
- HEDGEHOG_SIGNALING-0.268
- OXIDATIVE_PHOSPHORYLATION-0.248
- UNFOLDED_PROTEIN_RESPONSE-0.226
- SPERMATOGENESIS-0.148
- PANCREAS_BETA_CELLS-0.147
- MYC_TARGETS_V1-0.137
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1346813 | GTEX | — | 0.923 |
| 2 | SRR1488538 | GTEX | — | 0.894 |
| 3 | SRR612407 | GTEX | — | 0.892 |
| 4 | SRR1368856 | GTEX | — | 0.889 |
| 5 | SRR1323603 | GTEX | — | 0.886 |
| 6 | SRR1330498 | GTEX | — | 0.885 |
| 7 | SRR1350525 | GTEX | — | 0.883 |
| 8 | SRR615731 | GTEX | — | 0.883 |
| 9 | BS_47SJZ3PH | low-grade glioma | — | 0.882 |
| 10 | SRR613807 | GTEX | — | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.346 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.334 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.334 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.329 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.323 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.308 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.271 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.257 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.254 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.229 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.224 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.221 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.206 | Inavolisib | — uncovered |
| PEROXISOME | 0.204 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.155 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.152 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.143 | Inavolisib | — uncovered |
| MYOGENESIS | 0.126 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.112 | Inavolisib | — uncovered |